Effects of WY 47987 (atrial natriuretic factor 102-126) in patients with renal insufficiency: a placebo-controlled, randomised study
Details
Serval ID
serval:BIB_D36AA064A814
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effects of WY 47987 (atrial natriuretic factor 102-126) in patients with renal insufficiency: a placebo-controlled, randomised study
Journal
Nephrology Dialysis Transplantation
ISSN
0931-0509 (Print)
Publication state
Published
Issued date
1989
Volume
4
Number
9
Pages
776-81
Notes
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Abstract
We studied renal, hormonal and cardiovascular effects of ANF 102-126 (WY 47987) in seven patients with chronic renal failure (serum creatinine 25-68 mg/l) and in four normal volunteers. ANF or placebo bolus injections were given at 1, 2, and 3 micrograms/kg i.v. (each dose on separate days). As compared to placebo, ANF did not induce changes of renal excretory parameters, of plasma renin and aldosterone or of blood pressure and heart rate in patients. In healthy volunteers, however, the same dose of ANF increased urinary excretion of sodium, potassium, calcium, chloride and phosphorus as well as water, and creatinine clearances, and decreased plasma aldosterone. The data suggest blunted effectiveness of ANF bolus injections in patients with renal insufficiency.
Keywords
Aldosterone/blood
Atrial Natriuretic Factor/adverse effects/*therapeutic use
Hemodynamic Processes/drug effects
Humans
Kidney Failure, Chronic/*drug therapy
Male
Middle Aged
Natriuresis/drug effects
Peptide Fragments/adverse effects/*therapeutic use
Phosphorus/urine
Potassium/urine
Randomized Controlled Trials
Renin/blood
Pubmed
Web of science
Create date
05/03/2008 16:41
Last modification date
20/08/2019 15:53